BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000;58:251-259. [PMID: 10886570 DOI: 10.1046/j.1523-1755.2000.00160.x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Jang HS, Kim JI, Noh M, Rhee MH, Park KM. Regulator of G protein signaling 2 (RGS2) deficiency accelerates the progression of kidney fibrosis. Biochim Biophys Acta 2014;1842:1733-41. [PMID: 24973550 DOI: 10.1016/j.bbadis.2014.06.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
2 He W, Tan R, Dai C, Li Y, Wang D, Hao S, Kahn M, Liu Y. Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling. J Biol Chem 2010;285:24665-75. [PMID: 20519507 DOI: 10.1074/jbc.M109.091256] [Cited by in Crossref: 80] [Cited by in F6Publishing: 64] [Article Influence: 7.3] [Reference Citation Analysis]
3 陈辉, 马红. 纤溶酶原激活物抑制剂-1与肝纤维化. 世界华人消化杂志 2011; 19(11): 1156-1159 [DOI: 10.11569/wcjd.v19.i11.1156] [Reference Citation Analysis]
4 Kwaan HC, Lindholm PF. The Central Role of Fibrinolytic Response in COVID-19-A Hematologist's Perspective. Int J Mol Sci 2021;22:1283. [PMID: 33525440 DOI: 10.3390/ijms22031283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
5 Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE. Interactive Effect of PAI-1 4G/5G Genotype and Salt Intake on PAI-1 Antigen. ATVB 2001;21:1071-7. [DOI: 10.1161/01.atv.21.6.1071] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci (Landmark Ed) 2009;14:2028-41. [PMID: 19273183 DOI: 10.2741/3361] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
7 Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep. 2003;5:73-79. [PMID: 12530939 DOI: 10.1007/s11906-003-0014-0] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 6.5] [Reference Citation Analysis]
8 Fan JG, Chen LH, Xu ZJ, Zeng MD. Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver. World J Gastroenterol 2001; 7(5): 710-712 [PMID: 11819860 DOI: 10.3748/wjg.v7.i5.710] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol. 2005;16:966-976. [PMID: 15728787 DOI: 10.1681/asn.2004060492] [Cited by in Crossref: 107] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
10 Brown NJ, Vaughan DE, Fogo AB. The Renin-Angiotensin-Aldosterone System and Fibrinolysis in Progressive Renal Disease. Seminars in Nephrology 2002;22:399-406. [DOI: 10.1053/snep.2002.34725] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
11 Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003;326:15-24. [PMID: 12861121 DOI: 10.1097/00000441-200307000-00003] [Cited by in Crossref: 169] [Cited by in F6Publishing: 137] [Article Influence: 9.4] [Reference Citation Analysis]
12 Irani RA, Xia Y. Renin angiotensin signaling in normal pregnancy and preeclampsia. Semin Nephrol 2011;31:47-58. [PMID: 21266264 DOI: 10.1016/j.semnephrol.2010.10.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
13 Mezzano SA, Ruiz-ortega M, Egido J. Angiotensin II and Renal Fibrosis. Hypertension 2001;38:635-8. [DOI: 10.1161/hy09t1.094234] [Cited by in Crossref: 327] [Cited by in F6Publishing: 309] [Article Influence: 16.4] [Reference Citation Analysis]
14 Harris DC. Tubulointerstitial renal disease: . Current Opinion in Nephrology and Hypertension 2001;10:303-13. [DOI: 10.1097/00041552-200105000-00003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
15 Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020;194:101-15. [PMID: 32788101 DOI: 10.1016/j.thromres.2020.06.029] [Cited by in Crossref: 125] [Cited by in F6Publishing: 117] [Article Influence: 125.0] [Reference Citation Analysis]
16 Kelley R, Werdin ES, Bruce AT, Choudhury S, Wallace SM, Ilagan RM, Cox BR, Tatsumi-Ficht P, Rivera EA, Spencer T, Rapoport HS, Wagner BJ, Guthrie K, Jayo MJ, Bertram TA, Presnell SC. Tubular cell-enriched subpopulation of primary renal cells improves survival and augments kidney function in rodent model of chronic kidney disease. Am J Physiol Renal Physiol 2010;299:F1026-39. [PMID: 20826573 DOI: 10.1152/ajprenal.00221.2010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
17 Lassila M, Fukami K, Jandeleit-dahm K, Semple T, Carmeliet P, Cooper ME, Kitching AR. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia 2007;50:1315-26. [DOI: 10.1007/s00125-007-0652-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
18 Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney International 2001;59:804-19. [DOI: 10.1046/j.1523-1755.2001.059002804.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 4.9] [Reference Citation Analysis]
19 Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-173. [PMID: 32348783 DOI: 10.1016/j.cca.2020.04.027] [Cited by in Crossref: 151] [Cited by in F6Publishing: 134] [Article Influence: 151.0] [Reference Citation Analysis]
20 Song Y, Fan H, Tang X, Luo Y, Liu P, Chen Y. The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on ischemic stroke and the possible underlying mechanisms. Int J Neurosci 2021;:1-20. [PMID: 33653215 DOI: 10.1080/00207454.2021.1897588] [Reference Citation Analysis]
21 Del Pinto R, Ferri C. The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway. High Blood Press Cardiovasc Prev 2020;27:539-46. [PMID: 33047250 DOI: 10.1007/s40292-020-00414-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wilcox CS, Pitt B. Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19? J Cardiovasc Pharmacol 2020;77:323-31. [PMID: 33278189 DOI: 10.1097/FJC.0000000000000960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
23 Iwanami J, Mogi M, Iwai M, Horiuchi M. Inhibition of the renin-angiotensin system and target organ protection. Hypertens Res 2009;32:229-37. [PMID: 19262496 DOI: 10.1038/hr.2009.5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
24 Villa RF, Ferrari F, Moretti A. Effects of Neuroprotectants Before and After Stroke: Statins and Anti-hypertensives. In: Lapchak PA, Zhang JH, editors. Neuroprotective Therapy for Stroke and Ischemic Disease. Cham: Springer International Publishing; 2017. pp. 349-99. [DOI: 10.1007/978-3-319-45345-3_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Tiryaki O, Usalan C, Buyukhatipoglu H. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients. Nephrology 2010;15:211-5. [DOI: 10.1111/j.1440-1797.2009.01181.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
26 Şalaru DL, Mertens PR, Bartsch P. Loss of heparin-binding protein prevents necrotizing glomerulonephritis: first clues hint at plasminogen activator inhibitor-1. Int Urol Nephrol 2013;45:1483-7. [PMID: 23543126 DOI: 10.1007/s11255-013-0415-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Eddy AA. Plasminogen activator inhibitor-1 and the kidney. American Journal of Physiology-Renal Physiology 2002;283:F209-20. [DOI: 10.1152/ajprenal.00032.2002] [Cited by in Crossref: 135] [Cited by in F6Publishing: 125] [Article Influence: 7.1] [Reference Citation Analysis]
28 Tiryaki O, Usalan C, Buyukhatipoglu H, Sayiner ZA, Kilisli H. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients. Clin Exp Hypertens. 2012;34:145-152. [PMID: 21967026 DOI: 10.3109/10641963.2011.577491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
29 Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007;22:2011-22. [PMID: 17647026 DOI: 10.1007/s00467-007-0524-0] [Cited by in Crossref: 153] [Cited by in F6Publishing: 128] [Article Influence: 10.9] [Reference Citation Analysis]
30 Fogo AB. Renal fibrosis: not just PAI-1 in the sky. J Clin Invest 2003;112:326-8. [PMID: 12897200 DOI: 10.1172/JCI19375] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
31 Uma R, Forsyth JS, Struthers AD, Fraser CG, Godfrey V, Murphy DJ. Correlation of angiotensin converting enzyme activity and the genotypes of the I/D polymorphism in the ACE gene with preterm birth and birth weight. Eur J Obstet Gynecol Reprod Biol 2008;141:27-30. [PMID: 18755533 DOI: 10.1016/j.ejogrb.2008.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
32 Fogo AB. Progression versus regression of chronic kidney disease. Nephrology Dialysis Transplantation 2006;21:281-4. [DOI: 10.1093/ndt/gfi291] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
33 Paterna S, Di Garbo V, Avellone G, Di Pasquale P, Cacia A, Tuttolomondo A, Follone G, Cardinale A, Maniscalchi T, Licata G. Effects of Losartan and Delapril on the Fibrinolytic System in Patients with Mild to Moderate Hypertension: . Clinical Drug Investigation 2003;23:717-24. [DOI: 10.2165/00044011-200323110-00004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
34 Ekholm M, Kahan T, Jörneskog G, Brinck J, Wallén NH. Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion. J Renin Angiotensin Aldosterone Syst 2015;16:328-38. [PMID: 25908220 DOI: 10.1177/1470320315575848] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
35 Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900. [PMID: 12676174 DOI: 10.1016/s1357-2725(02)00271-6] [Cited by in Crossref: 441] [Cited by in F6Publishing: 173] [Article Influence: 24.5] [Reference Citation Analysis]
36 White M, Racine N, Ducharme A, de Champlain J. Therapeutic potential of angiotensin II receptor antagonists. Expert Opin Investig Drugs 2001;10:1687-701. [PMID: 11772278 DOI: 10.1517/13543784.10.9.1687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
37 Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-83. [PMID: 16102055 DOI: 10.1111/j.1538-7836.2005.01420.x] [Cited by in Crossref: 286] [Cited by in F6Publishing: 245] [Article Influence: 17.9] [Reference Citation Analysis]
38 Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005;67:1297-1307. [PMID: 15780082 DOI: 10.1111/j.1523-1755.2005.00207.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 6.9] [Reference Citation Analysis]
39 Ma L, Fogo AB. Modulation of glomerulosclerosis. Semin Immunopathol 2007;29:385-95. [DOI: 10.1007/s00281-007-0087-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
40 Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol. 2006;17:2999-3012. [PMID: 17035608 DOI: 10.1681/asn.2006050503] [Cited by in Crossref: 143] [Cited by in F6Publishing: 88] [Article Influence: 9.5] [Reference Citation Analysis]
41 Ramaha A, Patston PA. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. Arch Biochem Biophys 2002;397:77-83. [PMID: 11747312 DOI: 10.1006/abbi.2001.2687] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
42 Miyata T, Inagi R, Nangaku M, Imasawa T, Sato M, Izuhara Y, Suzuki D, Yoshino A, Onogi H, Kimura M, Sugiyama S, Kurokawa K. Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J Clin Invest 2002;109:585-93. [DOI: 10.1172/jci0214336] [Cited by in Crossref: 30] [Article Influence: 1.6] [Reference Citation Analysis]
43 Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift: . Journal of Hypertension 2001;19:829-42. [DOI: 10.1097/00004872-200105000-00001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 3.3] [Reference Citation Analysis]
44 Hao GH, Niu XL, Gao DF, Wei J, Wang NP. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 2008;153:1409-19. [PMID: 18278065 DOI: 10.1038/bjp.2008.21] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
45 Xia Y, Wen HY, Kellems RE. Angiotensin II Inhibits Human Trophoblast Invasion through AT1 Receptor Activation. Journal of Biological Chemistry 2002;277:24601-8. [DOI: 10.1074/jbc.m201369200] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
46 Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. American Journal of Physiology-Heart and Circulatory Physiology 2001;281:H2337-65. [DOI: 10.1152/ajpheart.2001.281.6.h2337] [Cited by in Crossref: 164] [Cited by in F6Publishing: 57] [Article Influence: 8.2] [Reference Citation Analysis]
47 Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2003;285:R1-R13. [DOI: 10.1152/ajpregu.00535.2002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 98] [Article Influence: 5.7] [Reference Citation Analysis]
48 Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney International 2004;66:1493-502. [DOI: 10.1111/j.1523-1755.2004.00913.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 6.9] [Reference Citation Analysis]
49 Chen HC, Feener EP. MEK1,2 response element mediates angiotensin II-stimulated plasminogen activator inhibitor-1 promoter activation. Blood 2004;103:2636-44. [PMID: 14656894 DOI: 10.1182/blood-2003-05-1737] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
50 Miyata T, Inagi R, Nangaku M, Imasawa T, Sato M, Izuhara Y, Suzuki D, Yoshino A, Onogi H, Kimura M, Sugiyama S, Kurokawa K. Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J Clin Invest 2002;109:585-93. [PMID: 11877466 DOI: 10.1172/JCI14336] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
51 Toblli JE, Derosa G, Cao G, Piorno P, Pagano P. ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats. Kidney International 2004;65:2343-59. [DOI: 10.1111/j.1523-1755.2004.00661.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
52 Schreckenberg R, Wolf A, Troidl C, Simsekyilmaz S, Schlüter KD. Pro-inflammatory Vascular Stress in Spontaneously Hypertensive Rats Associated With High Physical Activity Cannot Be Attenuated by Aldosterone Blockade. Front Cardiovasc Med 2021;8:699283. [PMID: 34381826 DOI: 10.3389/fcvm.2021.699283] [Reference Citation Analysis]
53 Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 2010;298:F683-91. [PMID: 20042458 DOI: 10.1152/ajprenal.00503.2009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
54 Ekholm M, Kahan T. The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19. Front Pharmacol 2021;12:640185. [PMID: 34220496 DOI: 10.3389/fphar.2021.640185] [Reference Citation Analysis]
55 Khairoun M, van den Heuvel M, van den Berg BM, Sorop O, de Boer R, van Ditzhuijzen NS, Bajema IM, Baelde HJ, Zandbergen M, Duncker DJ, Rabelink TJ, Reinders ME, van der Giessen WJ, Rotmans JI. Early systemic microvascular damage in pigs with atherogenic diabetes mellitus coincides with renal angiopoietin dysbalance. PLoS One 2015;10:e0121555. [PMID: 25909188 DOI: 10.1371/journal.pone.0121555] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
56 Lottermoser K, Hertfelder HJ, Gohlke P, Vetter H, Düsing R. Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects. Clin Exp Hypertens 2004;26:13-26. [PMID: 15000294 DOI: 10.1081/ceh-120027328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Sun Y. The Renin-Angiotensin-Aldosterone System and Vascular Remodeling. Congest Heart Failure 2002;8:11-6. [DOI: 10.1111/j.1527-5299.2002.00723.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
58 Uwaezuoke SN. The role of novel biomarkers in predicting diabetic nephropathy: a review. Int J Nephrol Renovasc Dis 2017;10:221-31. [PMID: 28860837 DOI: 10.2147/IJNRD.S143186] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
59 Yamaguchi I, Flynn JT. Pathophysiology of Hypertension. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1485-518. [DOI: 10.1007/978-3-540-76341-3_61] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
60 Cornell LD, Colvin RB. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens. 2005;14:229-234. [PMID: 15821415 DOI: 10.1097/01.mnh.0000165888.83125.07] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
61 Milei J, Cao G, Grana DR, Toblli JE. Plasminogen activator inhibitor-1 and transforming growth factor-beta 1 in carotid glomus and autonomic ganglia from spontaneously hypertensive rats. J Hypertens 2004;22:1351-9. [PMID: 15201552 DOI: 10.1097/01.hjh.0000125434.28861.9b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
62 Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006;20:101-8. [DOI: 10.1038/sj.jhh.1001960] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
63 Oestreicher EM, Martinez-Vasquez D, Stone JR, Jonasson L, Roubsanthisuk W, Mukasa K, Adler GK. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 2003;108:2517-23. [PMID: 14581407 DOI: 10.1161/01.CIR.0000097000.51723.6F] [Cited by in Crossref: 77] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
64 McConnell MJ, Kondo R, Kawaguchi N, Iwakiri Y. Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatol Commun 2021. [PMID: 34658172 DOI: 10.1002/hep4.1843] [Reference Citation Analysis]
65 Barra S, Silvestri N, Vitagliano G, Madrid A, Gaeta G. Angiotensin II receptor blockers in the prevention of atrial fibrillation. Expert Opin Pharmacother 2009;10:1395-411. [PMID: 19466911 DOI: 10.1517/14656560902973736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007;50:269-75. [PMID: 17576854 DOI: 10.1161/HYPERTENSIONAHA.107.091322] [Cited by in Crossref: 63] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
67 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost. 2005;3:35-45. [PMID: 15634264 DOI: 10.1111/j.1538-7836.2004.00827.x] [Cited by in Crossref: 205] [Cited by in F6Publishing: 187] [Article Influence: 12.8] [Reference Citation Analysis]
68 Ma L, Mao S, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, Mcguinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1. Diabetes 2004;53:336-46. [DOI: 10.2337/diabetes.53.2.336] [Cited by in Crossref: 280] [Cited by in F6Publishing: 246] [Article Influence: 16.5] [Reference Citation Analysis]
69 Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013;58:259-271. [PMID: 23313806 DOI: 10.1016/j.vph.2013.01.001] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 13.9] [Reference Citation Analysis]
70 Roldán V, Marín F. Are we content with lowering blood pressure alone, or should we be asking something more from the antihypertensive drugs we use?: effects of antihypertensive agents on fibrinolytic function. J Hum Hypertens 2004;18:681-3. [DOI: 10.1038/sj.jhh.1001754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Brown N, Bradford J, Wang Z, Lea W, Ma L, Ma J, Vaughan D, Fogo A. Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency. Kidney International 2007;72:72-81. [DOI: 10.1038/sj.ki.5002268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
72 Toblli JE, Cao G, DeRosa G, Forcada P. Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril. Heart 2005;91:80-6. [PMID: 15604340 DOI: 10.1136/hrt.2003.022707] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
73 Sobel BE, Taatjes DJ, Schneider DJ. Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis. ATVB 2003;23:1979-89. [DOI: 10.1161/01.atv.0000091250.53231.4d] [Cited by in Crossref: 77] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
74 Arndt PG, Young SK, Poch KR, Nick JA, Falk S, Schrier RW, Worthen GS. Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. J Immunol 2006;177:7233-41. [PMID: 17082641 DOI: 10.4049/jimmunol.177.10.7233] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
75 Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J Am Soc Nephrol 2005;16:2677-89. [PMID: 15987754 DOI: 10.1681/ASN.2004110945] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
76 Gando S, Wada T. Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. Front Immunol 2021;12:649122. [PMID: 34177896 DOI: 10.3389/fimmu.2021.649122] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
77 Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta 2008;29:763-71. [PMID: 18687466 DOI: 10.1016/j.placenta.2008.06.011] [Cited by in Crossref: 158] [Cited by in F6Publishing: 145] [Article Influence: 12.2] [Reference Citation Analysis]
78 Sobel BE, Schneider DJ. Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol Clin 2004;22:511-26. [PMID: 15501620 DOI: 10.1016/j.ccl.2004.06.009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
79 Gao BB, Hansen H, Chen HC, Feener EP. Angiotensin II stimulates phosphorylation of an ectodomain-truncated platelet-derived growth factor receptor-beta and its binding to class IA PI3K in vascular smooth muscle cells. Biochem J. 2006;397:337-344. [PMID: 16569213 DOI: 10.1042/bj20060095] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
80 Mohanram A, Toto RD. Outcome studies in diabetic nephropathy. Semin Nephrol 2003;23:255-71. [PMID: 12838494 DOI: 10.1016/s0270-9295(03)00061-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
81 Lee S, Lee S, Sharma K. The pathogenesis of fibrosis and renal disease in scleroderma: Recent insights from glomerulosclerosis. Curr Rheumatol Rep 2004;6:141-8. [DOI: 10.1007/s11926-004-0059-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
82 Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 2003;163:1261-73. [PMID: 14507636 DOI: 10.1016/s0002-9440(10)63486-4] [Cited by in Crossref: 163] [Cited by in F6Publishing: 87] [Article Influence: 9.1] [Reference Citation Analysis]
83 Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag 2008;4:89-101. [PMID: 18629353 DOI: 10.2147/vhrm.2008.04.01.89] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
84 Vaughan DE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001;87:18C-24C. [PMID: 11334764 DOI: 10.1016/s0002-9149(01)01509-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
85 Dagenais NJ, Jamali F. Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions. Pharmacotherapy 2005;25:1213-29. [DOI: 10.1592/phco.2005.25.9.1213] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 3.8] [Reference Citation Analysis]
86 Yia Y, Wne H, Bobst S, Day M, Kellems RE. Maternal Autoantibodies From Preeclamptic Patients Active Angiotensin Receptors on Human Trophoblast Cells. Journal of the Society for Gynecologic Investigation 2016;10:82-93. [DOI: 10.1016/s1071-55760200259-9] [Cited by in Crossref: 10] [Article Influence: 2.0] [Reference Citation Analysis]
87 Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics 2007;89:362-9. [PMID: 17207964 DOI: 10.1016/j.ygeno.2006.11.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
88 Ruiz-ortega M, Lorenzo O, Rupérez M, Esteban V, Suzuki Y, Mezzano S, Plaza J, Egido J. Role of the Renin-Angiotensin System in Vascular Diseases: Expanding the Field. Hypertension 2001;38:1382-7. [DOI: 10.1161/hy1201.100589] [Cited by in Crossref: 193] [Cited by in F6Publishing: 186] [Article Influence: 9.7] [Reference Citation Analysis]
89 Scholey JW. Angiotensin II and the glomerulus: Focus on diabetic kidney disease. Current Science Inc 2003;5:172-80. [DOI: 10.1007/s11906-003-0075-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
90 Bahraini M, Dorgalaleh A. The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19. Semin Thromb Hemost 2021. [PMID: 34695858 DOI: 10.1055/s-0041-1736166] [Reference Citation Analysis]
91 Dendorfer A, Dominiak P, Schunkert H. ACE Inhibitors and Angiotensin II Receptor Antagonists. In: von Eckardstein A, editor. Atherosclerosis: Diet and Drugs. Berlin: Springer Berlin Heidelberg; 2005. pp. 407-42. [DOI: 10.1007/3-540-27661-0_15] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
92 . Preface. In: Re RN, editor. Molecular Mechanisms in Hypertension. CRC Press; 2006. pp. 14-5. [DOI: 10.1201/b14627-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
93 Luther JM, Wang Z, Ma J, Makhanova N, Kim HS, Brown NJ. Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology 2009;150:2229-36. [PMID: 19106220 DOI: 10.1210/en.2008-1296] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
94 Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PM, Thomas WG. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol Rev. 2015;67:754-819. [PMID: 26315714 DOI: 10.1124/pr.114.010454] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 32.8] [Reference Citation Analysis]
95 Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005;16:3306-3314. [PMID: 16192423 DOI: 10.1681/asn.2004090804] [Cited by in Crossref: 125] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
96 Gipson DS, Gibson K, Gipson PE, Watkins S, Moxey-Mims M. Therapeutic approach to FSGS in children. Pediatr Nephrol 2007;22:28-36. [PMID: 17109140 DOI: 10.1007/s00467-006-0310-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
97 Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T, Noiri E, Fujita T. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 2007;25:1643-9. [PMID: 17620961 DOI: 10.1097/HJH.0b013e328165d159] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
98 van der Meer IM, Cravedi P, Remuzzi G. The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis Tissue Repair 2010;3:7. [PMID: 20441574 DOI: 10.1186/1755-1536-3-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
99 Ekholm M, Kahan T, Jörneskog G, Bröijersen A, Wallén N. Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. Thrombosis Research 2009;124:110-5. [DOI: 10.1016/j.thromres.2008.12.040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
100 Serdaroglu E, Mir S, Berdeli A, Aksu N, Bak M. ACE gene insertion/deletion polymorphism in childhood idiopathic nephrotic syndrome. Pediatr Nephrol 2005;20:1738-43. [DOI: 10.1007/s00467-005-2010-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
101 Suzaki Y, Prieto-Carrasquero MC, Kobori H. Intratubular Renin-Angiotensin System in Hypertension. Curr Hypertens Rev 2006;2:151-7. [PMID: 19789728 DOI: 10.2174/157340206776877325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
102 Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000;58:2425-36. [PMID: 11115076 DOI: 10.1046/j.1523-1755.2000.00426.x] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 5.4] [Reference Citation Analysis]
103 David P B. Is angiotensin II's role in fibrosis as easy as PAI(-1)? Kidney International 2000;58:460-1. [DOI: 10.1046/j.1523-1755.2000.00187.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
104 Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time. Hypertension 2002;40:859-65. [DOI: 10.1161/01.hyp.0000040264.15961.48] [Cited by in Crossref: 60] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
105 Prieto-carrasquero MC, Kobori H, Navar LG. The Intrarenal Renin-Angiotensin System. In: Carey RM, editor. Hypertension and Hormone Mechanisms. Totowa: Humana Press; 2007. pp. 3-22. [DOI: 10.1007/978-1-59259-987-5_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Tan M, Tang G, Rui H. Adiponectin attenuates Ang Ⅱ-induced TGFβ1 production in human mesangial cells via an AMPK-dependent pathway. Biotechnol Appl Biochem 2015;62:848-54. [PMID: 25471552 DOI: 10.1002/bab.1323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
107 Aroor AR, Shukla SD. Binge ethanol intake in chronically exposed rat liver decreases LDL-receptor and increases angiotensinogen gene expression. World J Hepatol 2011; 3(9): 250-255 [PMID: 21969878 DOI: 10.4254/wjh.v3.i9.250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
108 Passos-silva DG, Brandan E, Santos RAS. Angiotensins as therapeutic targets beyond heart disease. Trends in Pharmacological Sciences 2015;36:310-20. [DOI: 10.1016/j.tips.2015.03.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
109 Toto RD. Appropriate drug therapy for improving outcomes in diabetic nephropathy. Curr Diab Rep 2002;2:545-52. [DOI: 10.1007/s11892-002-0126-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
110 Inagi R, Miyata T, Suzuki D, Toyoda M, Wada T, Ueda Y, Izuhara Y, Sakai H, Nangaku M, Kurokawa K. Specific Tissue Distribution of Megsin, a Novel Serpin, in the Glomerulus and Its Up-Regulation in IgA Nephropathy. Biochemical and Biophysical Research Communications 2001;286:1098-106. [DOI: 10.1006/bbrc.2001.5509] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
111 Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003;4:43-55. [PMID: 12608526 DOI: 10.1046/j.1467-789x.2003.00091.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
112 Watanabe K, Togo S, Takahashi T, Matsuyama R, Yamamoto H, Shimizu T, Makino H, Matsuo K, Morioka D, Kubota T. PAI-1 plays an important role in liver failure after excessive hepatectomy in the rat. J Surg Res. 2007;143:13-19. [PMID: 17655862 DOI: 10.1016/j.jss.2007.04.041] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
113 Ma L, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney International 2001;59:1899-910. [DOI: 10.1046/j.1523-1755.2001.0590051899.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 137] [Article Influence: 7.5] [Reference Citation Analysis]